2008-05-09
Cultured Mucosal Substitutes; from Lab Bench towards Bedside?
Publication
Publication
Gekweekte orale slijmvliessubstituten, van laboratorium richting ziekenbed?
Abstract
Oral cancer is the sixth most common cancer in the world. It accounts for approximately 4% of all cancers and 2% of all cancer deaths worldwide. Malignant tumors of the oral cavity account for approximately 30% of all head and neck cancers. With an incidence rate of invasive lip and oral cavity tumors in The Netherlands rising to 6.6%, oral cancer is a common malignancy that often requires resection of the tumor followed by reconstruction.
| Additional Metadata | |
|---|---|
| , , | |
| Erasmus University Rotterdam | |
| S.E.R. Hovius (Steven) | |
| Allergan Artu Biologicals Biomet Bioprof Bloom Medical Covidien Dutch Burns Foundation Emdaplast Erasmus University Rotterdam Copyright © Hinne A Rakhorst Esser foundation Johnson & Johnson: Mitek, Woundcare and Ethicon KCI Molnlycke Dutch Society for Plastic and Reconstructive Surgery Valeant | |
| hdl.handle.net/1765/11767 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Rakhorst, H. (2008, May 9). Cultured Mucosal Substitutes; from Lab Bench towards Bedside?. Retrieved from http://hdl.handle.net/1765/11767 |
|
